Efficacy of 24-week treatment with compound aspirin on platelet aggregation in patients with cardiovascular disease

Objective: To evaluate the inhibition of platelet aggregation after 24-week therapy of compound aspirin(dihydroxyaluminum aminoacetate-heavy magnesium carbonate-aspirin) in cardiovascular patients.Methods: A total of 103 cardiovascular patients with high platelet aggregation rate were enrolled,who needed the treatment of aspirin.They were treated with oral doses of dihydroxyaluminum aminoacetate-heavy magnesium carbonate-aspirin(contain 162 mg aspirin) daily for 24 weeks.Platelet aggregation was measured before and 6,12,24 weeks after administration.Results: The platelet aggregation was significantly inhibited 6,12 and 24 weeks after administration.There were significant differences in the platelet aggregation between baseline and post-treatment.The inhibition rate of platelet aggregation at 6,12,24 weeks after administration were-(20.49±22.35)%,-(28.10±22.88)%,and-(23.23±22.68)%,respectively.The platelet aggregation was inhibited at 12 weeks more than at 6 weeks follow-up,but less at 24 weeks than at 12 weeks follow-up(P0.05).Conclusion: The inhibitive effect of dihydroxyaluminum aminoacetate-heavy magnesium carbonate-aspirin tablet on platelet aggregation is conclusive;however,this effect is lower at 24 weeks than at 12 weeks.